Syndax Pharmaceuticals to Report Q3 2026 Results Nov. 2
Biopharmaceutical stakeholders will gain insight into the company's commercial performance during the upcoming webcast.
Updated on Oct. 26, 2026 in Corporate Finance
Syndax Pharmaceuticals will report its third quarter 2026 financial results on November 2, 2026. The company will host an accompanying investor conference call and webcast at 4:30 p.m. ET that same day.
Why it matters
Financial reporting updates provide essential data for investors and industry peers to evaluate the market performance of commercial-stage biopharmaceutical companies. These disclosures allow stakeholders to assess the revenue trajectory and operational viability of key pipeline products.
Syndax Pharmaceuticals will report financial results for the third quarter of 2026 on November 2, with a 90-day replay window provided for the investor call. Financial disclosures for the period remain pending as the company prepares to detail performance for products Revuforj and Niktimvo.
The players
Syndax Pharmaceuticals
A commercial-stage biopharmaceutical company focused on the development of oncology therapies including Revuforj and Niktimvo.
The details
The company will broadcast a live audio webcast and conference call to review the quarter's financial outcomes. Interested participants may access the call via domestic dial-in at 800-590-8290 or international line 240-690-8800 using conference ID Syndax3Q26. Slides and the webcast stream will be published on the firm's investor portal.
Timeline
November 2, 2026: Financial results report and conference call.
4:30 p.m. ET, November 2, 2026: Conference call and webcast start time.
Market Landscape
This reporting event follows the standard periodic disclosure cycle required for public companies under Securities and Exchange Commission guidelines. It provides a necessary update on commercial-stage operations for a firm actively managing its product pipeline.
Operators and investors should monitor the November 2 release to gauge the commercial uptake of the company's oncology pipeline. Stakeholders should ensure they have the conference ID Syndax3Q26 ready if planning to join the live session.
The takeaway
The upcoming results offer a key signal for the commercial success of the firm's current drug portfolio. Operators should plan to monitor the disclosure for updates on product-specific performance metrics that indicate broader biopharma market trends.
What happens next
A replay of the investor conference call will be accessible for 90 days following the November 2, 2026 event.
Further reading
For broader trends in industry performance disclosures, visit the Corporate Finance section.
More information
Access the conference call slides and materials on the Syndax corporate investor website.
